Asimov has unveiled its AAV Edge Stable Producer system, a synthetic biology breakthrough that stably integrates viral genes into HEK293 cells to produce high-titer AAV vectors without transient plasmid transfection. This innovation addresses key manufacturing challenges in AAV gene therapy by improving scalability, reducing costs, and enhancing product consistency. By enabling bioreactor scale-up and eliminating batch variability, the technology promises safer and more affordable gene therapies supported by pharma partnerships.